1.2 OMIM# of the disease 114290.
1.3 Name of the analysed genes or DNA/chromosome segments SOX9.
OMIM# of the gene(s)
608160.
Mutational spectrum
The majority of mutations are point mutations (missense, nonsense, splice site mutations), but also short insertions/deletions causing frameshifts. 1 Missense mutations cluster exclusively in the DNAbinding HMG domain, 1 but for two that have been found so far in the dimerization domain of SOX9. 2, 3 Larger deletions covering SOX9 4, 5 or located upstream of SOX9 5,6 have occasionally been described. A few percent of cases are due to inversions or translocations interrupting the 1-Mb regulatory domain of SOX9. [7] [8] [9] [10] A single publication describes cases with brachydactyly and anonychia, a phenotype compatible with Cooks syndrome MIM 106995 11 due to microduplications of noncoding elements 5 0 of SOX9. Missense mutations and translocations are overrepresented in CD cases without overt bending of the long bones (ACD). 10, [12] [13] [14] Of note, individuals with translocation breakpoints or deletions located greater than 1 Mb upstream of SOX9 only show isolated Pierre Robin sequence and none of the other clinical symptoms of CD/ACD. 15, 16 Similarly, several duplications and a deletion of a region B0.5 Mb upstream of SOX9 have been reported, which only lead to isolated disorders of sexual development. [17] [18] [19] 1.6 Analytical methods The main strategy for mutation screening consists in sequencing of the three SOX9 exons and exon/intron boundaries, which allows for the detection of B90% of mutations in CD/ACD cases. This may need to be followed by screening for large deletions by quantitative PCR or array CGH, and by cytogenetic analyses to detect translocations or larger inversions, which brings the detection rate to B95%.
Analytical validation
The existence of a mutation is confirmed by sequencing a second, independent PCR product from the patient's sample.
1.8 Estimated frequency of the disease (incidence at birth ('birth prevalence') or population prevalence if known to be variable between ethnic groups, please report) 1 in 40 000 to 1 in 80 000.
Diagnostic setting
Yes No
CD is due to de novo heterozygous mutations in SOX9, with recurrence risk of a few percent (estimate B5%) due to germ line mosaicism in one of the parents. A predictive prenatal testing is thus only possible if a SOX9 mutation has been identified in a previous pregnancy. Specificity:
TEST CHARACTERISTICS
Negative predictive value:
2.1 Analytical sensitivity (proportion of positive tests if the genotype is present) About 95%. 3.1.2 Describe the burden of alternative diagnostic methods to the patient Definitive diagnosis of CD is feasible in a majority of affected individuals based on radiological findings, such as bowing of the femora and tibiae, hypoplasia of the scapulae, widely spaced vertical ischia and hypoplastic pubes, and hypoplastic cervical vertebrae. However, the molecular test for SOX9 and its regulatory domain is important for several reasons. Affected individuals with aberration of the regulatory domain and chromosome derangement tend to have better clinical outcomes. In addition, a subset of patients does not show the full skeletal manifestation, but a few skeletal changes only (eg, brachydactyly or Pierre Robin sequence). 
Prenatal diagnosis
(To be answered if in 1.9 'D' was marked) Early genetic testing from chorionic villi is possible. Routine ultrasound readily reveals bowing and shortening of the femora. However, meticulous assessment is mandatory to identify more specific findings, such as hypoplastic scapulae. CD, unlike other severe skeletal dysplasias, frequently shows only mild femoral shortening and only mild or no bowing. Thus, 'ACD' tends to be overlooked, although its clinical presentation is, in most cases, as severe as that of classic cases.
3.4.1 Does a positive genetic test result in the index patient enable a prenatal diagnostic? Yes.
IF APPLICABLE, FURTHER CONSEQUENCES OF TESTING
Please assume that the result of a genetic test has no immediate medical consequences. Is there any evidence that a genetic test is nevertheless useful for the patient or his/her relatives? (Please describe) A positive genetic test outcome provides an unequivocal diagnosis of CD in patients whose clinical and radiological symptoms are not clearcut. This alleviates psychological stress due to uncertain diagnosis, makes additional genetic testing for other suspected skeletal disorders obsolete and allows to offer prenatal testing in a further pregnancy at risk of recurrence of B5% from germline mosaicism.
